Category: 3. Business

  • Department of Labor & Workforce Development

    December 15, 2025

    TRENTONInvestigators from the New Jersey Department of Labor and Workforce Development’s (NJDOL) Division of Wage and Hour Compliance issued the following stop-work order on December 3, 2025: 

    Employer: All American Drywall LLC of Jersey City, N.J. (subcontractor)
    Work Locations: Three sites in Jersey City, N.J. – 25 Cottage Street, 35 Cottage Street, and 10 Journal Square.
    Nature of Work: Construction maintenance
    Details: All American Drywall LLC was hired to the three projects in the Journal Square neighborhood by primary contractor A.J.D. Construction Co. Inc. of Leonardo, N.J. NJDOL previously issued stop-work orders to four other subcontractors working at 10 Journal Square Plaza earlier this year.
    Violations: Improper classification of construction workers; failing to properly classify employees; not paying overtime; unpaid wages/late payment; no Earned Sick Leave records; Earned Sick Leave notification/posting violations; and hindrance/failure to provide records.
    Workers Affected: 53 

    NJDOL has issued 211 stop-work orders since these powers were expanded in July 2019. 

    Stop-work orders are initiated by NJDOL to halt work being performed in a manner that exploits workers, or is otherwise noncompliant with state laws and regulations. An employer may appeal a stop-work order, in which case NJDOL has seven days to schedule a hearing. 

    NJDOL continues to monitor locations where stop-work orders have been issued, and can assess civil penalties of $5,000 per day against an employer conducting business in violation of the order. The stop-work order may be lifted if and when any remaining back wages and penalties have been paid and all related issues have been resolved. 

    For more information on worker benefits and protections, please visit myworkrights.nj.gov. 

    Go back to all press releases

    Continue Reading

  • Winston Y. Chan Speaks with Daily Journal After Being Named a Top White-Collar Lawyer for 2025

    Winston Y. Chan Speaks with Daily Journal After Being Named a Top White-Collar Lawyer for 2025

    Accolades  |  December 15, 2025

    Daily Journal


    In an interview with the Daily Journal after being named one of its Top White-Collar Lawyers for 2025, partner Winston Y. Chan discussed leading the defense team for a technology company involved in three concurrent investigations by the U.S. Department of Justice, Securities and Exchange Commission, and California Attorney General. Each agency investigated different theories of whether the company misrepresented cybersecurity events and weaknesses to customers and investors. The team faced extensive and competing document, information, and interview requests from all three agencies.

    “These were open-ended investigations in search of a whisper of a problem,” Winston said.

    Earlier this year, all three agencies closed their investigations without taking action against the company.

    Winston is Co-Chair of both our global White Collar Defense and Investigations Practice Group and our False Claims Act/Qui Tam Defense Practice Group. He noted several changes in False Claims Act enforcement under the Trump administration.

    “Not in my entire career working on FCA cases have I seen so many novel applications of the statute being pursued all at once, in such a public way, with top-down pronouncements designed to motivate DOJ staff as well as putative whistleblowers and their counsel,” Winston said.

    Continue Reading

  • Should U.S. be worried about AI bubble? — Harvard Gazette

    Should U.S. be worried about AI bubble? — Harvard Gazette

    Tech giants Amazon, Meta, Alphabet, Microsoft, and Oracle have been taking on enormous new debt in a race to build out their artificial intelligence ventures in the last year, fueling Wall Street fears of a bubble capable of disrupting the entire economy.

    In this edited conversation, Andy Wu, Arjun and Minoo Melwani Family Associate Professor of Business Administration at Harvard Business School, explains why AI hyperscalers — firms that operate, or will need to operate, massive, global data centers — are taking on enormous liabilities and whether investors are right to worry about a possible AI bubble.


    Why are generative AI firms fundraising so aggressively?

    Generative AI is perhaps the most exciting technology since the rise of the internet. That excitement has attracted a significant amount of attention from private equity, venture capital, and public equity investors.

    I agree with the consensus about the long-term value creation potential of generative AI. But achieving that long-term vision requires a capital-intensive infrastructure buildout. We need more data centers, more chips, and more electricity to handle the escalating computing needed to both create frontier AI models (training) and use them (inference).

    “While generative AI can do amazing things, it is also perhaps the most wasteful use of a computer ever devised.”

    Andy Wu

    While generative AI can do amazing things, it is also perhaps the most wasteful use of a computer ever devised. If you do 1+1 on a calculator, that’s one calculation. If you do 1+1 in generative AI, that is potentially a trillion calculations to get an answer. That consumes a huge amount of chip capacity and electricity.

    And so, many companies are attempting to build out that capacity by buying chips, building data centers, and, in some cases, even buying and building nuclear power plants to power those facilities.

    The issue is that someone has to incur the fixed cost of the buildout today for the potential of long-term profit in the future. That long-term profit is hypothetical and has not been realized yet. The companies leading this buildout have taken on significant debt alongside unprecedented levels of equity financing.

    As the market for cloud computing grows, it becomes more competitive and, in some ways, less attractive.

    If you asked me five years ago, I would have said the market for public cloud infrastructure was only big enough for three hyperscalers. But now that there’s so much more demand for computing, more companies can reach the economies of scale to be viable.

    Just a few years ago, Oracle was not a part of the conversation. But the growing market has dramatically lifted Oracle and allowed it to become economically viable and competitive with Microsoft, Google, and Amazon.

    Several companies, and especially the neoclouds that specialize in renting out GPUs [graphics processing units], have borrowed significant amounts premised on hypothetical cash flows in the future. So they’re borrowing money now to build a data center that they expect to get paid for by somebody else in the future.

    For instance, OpenAI has promised $100 billion contracts to several of its vendors. OpenAI today does not generate anywhere near the amount of revenue to pay for any of that.

    Those vendors have raised money to build data centers on the assumption OpenAI is going to pay them $100 billion later. If OpenAI cannot grow revenue fast enough to meet those commitments, several of those vendors will be underwater financially.

    Is that buildout truly needed right now?

    The industry faces two contradictory timing problems. On one hand, from a long-term perspective, my view is that the scale of buildout is absolutely necessary to facilitate AI. If anything, we’re probably too slow: not just on the data center side, but especially on the electrical grid.

    But on the other hand, the risk right now is the gap between the long-term vision of AI and whether or not the growth will materialize fast enough to pay for the buildout. The subtlety here is that these companies can end up underwater if AI grows fast but less rapidly than they hope for.

    Why such apprehension over AI borrowing and spending?

    First, it’s become apparent how much money has been borrowed. Financing losses with equity investment is one thing. But defaulting on debt has much more disruptive consequences for the companies involved and our economy as a whole.

    Second, there are unusual “circular financing” arrangements between customers and suppliers that have drawn attention.  To some, it appears that Nvidia is paying its customers to buy its products. Certainly, there’s some scenario where vendor financing is justifiable, but it certainly raises eyebrows here.

    More generally, the bigger issue is downstream. For the potential customers of the data centers — the companies training models or running inference — there’s no short-term scenario in which they are economically viable given how costly it is today. The customers of the data centers are not themselves profitable, and they have no immediate way of generating enough revenue to cover the cost of compute.

    “What’s critical to understand, but overlooked by most users, is that generative AI has a significant variable cost.”

    Andy Wu

    What’s critical to understand, but overlooked by most users, is that generative AI has a significant variable cost. It costs OpenAI real money every time we ask ChatGPT something and ChatGPT responds.

    OpenAI CEO Sam Altman once joked saying, “Please” and “Thank you” to ChatGPT costs them millions of dollars. For now, as AI applications grow their customer base and usage, they lose more money. Growth itself does not fix the economics.

    Do you see signs of an AI bubble?

    In my research on technology strategy, I often look back at the history of the technology industry for hints on how to think about the future.

    Technology regularly goes through these ups and downs. The dotcom bubble is the most famous, but in recent years, we’ve had a work-from-home bubble with Peloton and Zoom. We’ve had a bunch of crypto bubbles. There was a virtual reality bubble. In the mid-2010s, we had a gig economy bubble.

    It’s easy to get overexuberant about technology.

    I would define a bubble in technology as when there’s a significant mismatch between the vision for potential value creation and the current reality of value capture. In other words: Everyone can imagine how useful the technology will be, but no one has figured out yet how to make money. This mismatch puts companies currently operating in a very difficult position.

    Regardless of the long-term legitimacy of their offering, they have real financial obligations they have to meet today that they may not be able to meet. What separates a hype cycle that goes away without much fanfare versus a truly destructive bubble is the amount of leverage and risk being taken by the investors and vendors.  

    Given AI’s importance, what effect could an AI bust have on the U.S. economy?

    Big tech is largely insulated from the risks of this. They’ve taken a shrewd and conservative strategy for AI. They positioned themselves well to benefit from the rise of AI, but they don’t stand to lose that much if AI grows slower than anticipated.

    Why won’t Big Tech lose much if AI falters?

    First, Microsoft has mostly outsourced AI to a third party, OpenAI. Second, Amazon will support anybody’s AI model, seemingly indifferent to the specifics. Third, Meta spent billions of dollars building an open-source AI model that they hand out for free to the world.

    If you take those three facts in conjunction, what that’s saying is that these companies don’t really think that core AI technology is a meaningful business in and of itself.

    “If you take those three facts in conjunction, what that’s saying is that these companies don’t really think that core AI technology is a meaningful business in and of itself.”

    Andy Wu

    Instead, they’re focused on profiting from all the adjacencies to AI. I often use a gold rush analogy: OpenAI, Anthropic, and xAI are out there digging for gold.

    Nvidia is the consummate shovel seller, designing the chips needed by the gold diggers. And Meta is the consummate jewelry maker: Meta’s social media, advertising, wearables, and metaverse businesses stand to benefit from advancements in generative AI, wherever it comes from and whenever it comes. Microsoft does a bit of shovel selling and jewelry making, but the key thing is they’re not stuck digging for gold.

    Certainly, it’s plausible that Amazon and Microsoft and Google might make less money on their cloud computing than they ideally would like if AI growth slows or declines, but they would not end up in financial distress. They still have plenty of customers absent AI.

    Who is most exposed if AI fizzles out?

    The model builders and the neoclouds, because they’re entirely dependent on a very particular growth trajectory of AI.

    What should AI investors keep in mind?

    As John Maynard Keynes allegedly once said, the markets can remain irrational longer than you can remain solvent.

    But there is an important nuance that Keynes missed. Any ambitious vision for a new technology rests on faith in the unproven, so backing it inherently demands a degree of irrationality. If the market can keep the faith to persist, it buys the necessary time for the technology to mature, for the costs to come down, and for companies to figure out the business model.

    In other words, if the market can remain irrational long enough, the vision eventually becomes the reality.


    Continue Reading

  • FDA Takes Action to Improve Recall Effectiveness Following Infant Botulism Outbreak Investigation Linked to ByHeart Infant Formula – fda.gov

    1. FDA Takes Action to Improve Recall Effectiveness Following Infant Botulism Outbreak Investigation Linked to ByHeart Infant Formula  fda.gov
    2. 51 babies across 19 states fall ill from botulism linked to ByHeart baby formula  Fox Business
    3. Target, Walmart, Kroger and Albertson – are you greedy, stupid or both? You can’t get Botulism off your shelves?  Marler Blog
    4. US FDA sends warning letters to Walmart, Target for selling recalled baby formula  Reuters
    5. CDC Expands Botulism Case Definition as ByHeart Formula Recall Continues  The Pride LA

    Continue Reading

  • Enhertu plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer

    Notes

    HER2-positive metastatic breast cancer
    Breast cancer is the second most common cancer and one of the leading causes of cancer-related deaths worldwide.2 More than two million breast cancer cases were diagnosed in 2022, with more than 665,000 deaths globally.2 In the US, more than 300,000 cases of breast cancer are diagnosed annually with more than 42,000 deaths.3 While survival rates are high for those diagnosed with early breast cancer, only about 30% of patients diagnosed with or who progress to metastatic disease are expected to live five years following diagnosis.4

    HER2 is a tyrosine kinase receptor growth-promoting protein expressed on the surface of many types of tumours including breast cancer.5 HER2 protein overexpression may occur as a result of HER2 gene amplification.6 Approximately one in five cases of breast cancer are considered HER2-positive.7

    HER2-positive metastatic breast cancer is an aggressive disease driven by overexpression or amplification of HER2.8 Approximately 10,000 patients are treated each year in the 1st-line HER2-positive metastatic setting in the US.9 While HER2-targeted therapies have improved outcomes, prognosis remains poor with most patients experiencing disease progression within two years of 1st-line treatment with THP, which has been the standard of care for more than a decade.6,10-12 Approximately 25% to 30% of patients do not receive any treatment following 1st-line therapy due to discontinuation or death.13-15

    DESTINY-Breast09
    DESTINY-Breast09 is a global, multicentre, randomised, open-label, Phase III trial evaluating the efficacy and safety of Enhertu (5.4 mg/kg) either alone or in combination with pertuzumab versus standard of care THP as a 1st-line treatment in patients with HER2-positive metastatic breast cancer.

    Patients were randomised 1:1:1 to receive either Enhertu monotherapy with a pertuzumab matching placebo; Enhertu in combination with pertuzumab; or THP. Randomisation was stratified by prior treatment (de novo metastatic disease versus progression from early-stage disease), hormone receptor (HR) status and PIK3CA mutation status.

    The primary endpoint of DESTINY-Breast09 is PFS as assessed by blinded-independent central review in the Enhertu monotherapy and Enhertu combination arms. Secondary endpoints include investigator-assessed PFS, overall survival, objective response rate, duration of response, pharmacokinetics and safety. The investigational arm assessing Enhertu monotherapy versus THP remains blinded to patients and investigators and will continue to the final PFS analysis.

    DESTINY-Breast09 enrolled 1,157 patients across multiple sites in Africa, Asia, Europe, North America and South America. For more information about the trial, visit ClinicalTrials.gov.

    Enhertu
    Enhertu is a HER2-directed ADC. Designed using Daiichi Sankyo’s proprietary DXd ADC Technology, Enhertu is the lead ADC in the oncology portfolio of Daiichi Sankyo and the most advanced programme in AstraZeneca’s ADC scientific platform. Enhertu consists of a HER2 monoclonal antibody attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers.

    Enhertu (5.4mg/kg) in combination with pertuzumab is approved in the US as a 1st-line treatment for adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer, as determined by an FDA-approved test based on the results from the DESTINY-Breast09 trial.

    Enhertu (5.4mg/kg) is approved in more than 90 countries/regions worldwide for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer who have received a prior anti-HER2-based regimen, either in the metastatic setting or in the neoadjuvant or adjuvant setting, and have developed disease recurrence during or within six months of completing therapy based on the results from the DESTINY-Breast03 trial.

    Enhertu (5.4mg/kg) is approved in more than 85 countries/regions worldwide for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received a prior systemic therapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy based on the results from the DESTINY-Breast04 trial.

    Enhertu (5.4mg/kg) is approved in more than 55 countries/regions worldwide for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by a locally or regionally approved test, that have progressed on one or more endocrine therapies in the metastatic setting based on the results from the DESTINY-Breast06 trial.

    Enhertu (5.4mg/kg) is approved in more than 60 countries/regions worldwide for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumours have activating HER2 (ERBB2) mutations, as detected by a locally or regionally approved test, and who have received a prior systemic therapy based on the results from the DESTINY-Lung02 and/or DESTINY-Lung05 trials. Continued approval in China and the US for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

    Enhertu (6.4mg/kg) is approved in more than 70 countries/regions worldwide for the treatment of adult patients with locally advanced or metastatic HER2-positive (IHC 3+ or IHC 2+/ISH+) gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen based on the results from the DESTINY-Gastric01, DESTINY-Gastric02 and/or DESTINY-Gastric06 trials. Continued approval in China for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

    Enhertu (5.4mg/kg) is approved in more than 10 countries/regions worldwide for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumours who have received prior systemic treatment and have no satisfactory alternative treatment options based on efficacy results from the DESTINY-PanTumor02, DESTINY-Lung01 and DESTINY-CRC02 trials. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

    Enhertu development programme
    A comprehensive global clinical development programme is underway evaluating the efficacy and safety of Enhertu as a monotherapy, in combination or sequentially with other cancer medicines across multiple HER2-targetable cancers.

    Daiichi Sankyo collaboration
    AstraZeneca and Daiichi Sankyo entered into a global collaboration to jointly develop and commercialise Enhertu in March 2019 and Datroway (datopotamab deruxtecan) in July 2020, except in Japan where Daiichi Sankyo maintains exclusive rights for each ADC. Daiichi Sankyo is responsible for the manufacturing and supply of Enhertu and Datroway.

    AstraZeneca in breast cancer
    Driven by a growing understanding of breast cancer biology, AstraZeneca is challenging, and redefining, the current clinical paradigm for how breast cancer is classified and treated to deliver even more effective treatments to patients in need – with the bold ambition to one day eliminate breast cancer as a cause of death.

    AstraZeneca has a comprehensive portfolio of approved and promising compounds in development that leverage different mechanisms of action to address the biologically diverse breast cancer tumour environment.

    With Enhertu, AstraZeneca and Daiichi Sankyo are aiming to improve outcomes in patients with HER2-positive, HER2-low and HER2-ultralow metastatic breast cancer and are exploring its potential in earlier lines of treatment and in new breast cancer settings.

    In HR-positive breast cancer, AstraZeneca continues to improve outcomes with foundational medicines Faslodex (fulvestrant) and Zoladex (goserelin) and aims to reshape the HR-positive space with first-in-class AKT inhibitor, Truqap (capivasertib), the TROP2-directed ADC, Datroway (datopotamab deruxtecan), and next-generation oral SERD and potential new medicine camizestrant.

    PARP inhibitor Lynparza (olaparib) is a targeted treatment option that has been studied in early and metastatic breast cancer patients with an inherited BRCA mutation. AstraZeneca with MSD (Merck & Co., Inc. in the US and Canada) continue to research Lynparza in these settings. AstraZeneca is also exploring the potential of saruparib, a potent and selective inhibitor of PARP1, in combination with camizestrant in BRCA-mutated, HR-positive, HER2-negative advanced breast cancer.

    To bring much-needed treatment options to patients with triple-negative breast cancer, an aggressive form of breast cancer, AstraZeneca is collaborating with Daiichi Sankyo to evaluate the potential of Datroway alone and in combination with immunotherapy Imfinzi (durvalumab). 

    AstraZeneca in oncology
    AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients.

    The Company’s focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyse changes in the practice of medicine and transform the patient experience.

    AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.

    AstraZeneca
    AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca.

    Contacts
    For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

    Continue Reading

  • Attorney General Paxton Sues Five Major TV Companies, Including Some with Ties to the CCP, for Spying on Texans

    Attorney General Paxton Sues Five Major TV Companies, Including Some with Ties to the CCP, for Spying on Texans

    Attorney General Ken Paxton has filed suit against five major television companies for spying on Texans by secretly recording what consumers watch in their own homes. The five major corporations being sued are as follows: Sony, Samsung, LG, as well as Hisense and TCL Technology Group Corporation (“TCL”), which are both based in China. These Chinese ties pose serious concerns about consumer data harvesting and are exacerbated by China’s National Security Law, which gives its government the capability to get its hands on U.S. consumer data. 

    These companies have been unlawfully collecting personal data through Automated Content Recognition (“ACR”) technology. ACR in its simplest terms is an uninvited, invisible digital invader. This software can capture screenshots of a user’s television display every 500 milliseconds, monitor viewing activity in real time, and transmit that information back to the company without the user’s knowledge or consent. The companies then sell that consumer information to target ads across platforms for a profit. This technology puts users’ privacy and sensitive information, such as passwords, bank information, and other personal information at risk.

    “Companies, especially those connected to the Chinese Communist Party, have no business illegally recording Americans’ devices inside their own homes,” said Attorney General Paxton. “This conduct is invasive, deceptive, and unlawful. The fundamental right to privacy will be protected in Texas because owning a television does not mean surrendering your personal information to Big Tech or foreign adversaries.”

    Attorney General Paxton remains committed to holding corporations accountable for deceptive, abusive, or exploitative practices. The Office of the Attorney General recognizes the ongoing threat posed by the Chinese Communist Party to the safety, data security, and personal privacy of Texans, and will continue to aggressively investigate and stop any company that puts consumers at risk.

    Click to read the lawsuits against Sony, Samsung, LG, Hisense, and TCL. 

    Continue Reading

  • Governor Lamont Announces Additional 40,000 Connecticut Residents To Have Medical Debt Erased

    Governor Lamont Announces Additional 40,000 Connecticut Residents To Have Medical Debt Erased

    (HARTFORD, CT) – Governor Ned Lamont today announced that nearly 40,000 Connecticut residents will receive letters in the mail this week informing them that some or all of their medical debt has been erased under an initiative the Lamont administration launched last year in partnership with the national nonprofit organization Undue Medical Debt to give relief to those who are having difficulties paying medical bills.

    This third round of the initiative is eliminating more than $63 million in medical debt. In total, nearly 160,000 Connecticut residents who’ve been struggling with bills have had $198 million in medical debt eliminated since the initiative began in December 2024.

    “Medical debt can delay healing due to stress and anxiety about how to pay these bills,” Governor Lamont said. “With this latest round of letters being sent out to Connecticut residents, we will have eliminated $198 million in medical debt over the last year. This makes a real difference in the lives of our families, reducing fear and concerns. My administration continues to work with other medical providers to help additional families, and I urge all of them to step up and be part of the solution to address the cost of healthcare in Connecticut.”

    Under the initiative, Undue Medical Debt leverages investments from the state to negotiate with hospitals and other providers on the elimination of large, bundled portfolios of qualifying medical debt owed by Connecticut patients. Those who qualify must have income at or below four times (400%) the federal poverty level or have medical debt that is 5% or more of their income. (The current federal poverty level is an annual income at or below $32,150 for a family of four.) Since these medical debts are acquired in bulk and belong to those least able to pay, they cost a fraction of their face value, often pennies on the dollar.

    Connecticut residents who have been identified for debt relief will receive an Undue Medical Debt branded envelope containing a letter from Undue Medical Debt in the mail over the next several days. (To view a sample of what this letter looks like, click here.)

    Because this debt erasure occurs through the purchase of large, qualifying bundled portfolios of debt from participating partners like hospitals and collection agencies, there is no application process for this relief and it cannot be requested.

    “I’m grateful to Governor Lamont and Connecticut for their continued leadership in providing medical debt relief to residents across the state,” Allison Sesso, CEO and president of Undue Medical Debt, said. “This third round builds on tremendous progress — nearly 160,000 people helped and $198 million in debts of necessity erased. Medical debt creates both financial strain and emotional burdens that prevent families from seeking the care they need. We’re proud to partner with Connecticut’s community-minded providers who recognize that removing these unpayable debts helps their patients and communities thrive, and we look forward to bringing relief to even more families in the future.”

    The first round of the initiative in December 2024 erased approximately $30 million in medical debt for approximately 23,000 people; and the second round in May 2025 erased more than $100 million in medical debt for 100,000 people.

    Governor Lamont intends to continue partnering with Undue Medical Debt to enact further rounds of medical debt cancellation. The governor and the Connecticut General Assembly enacted legislation that makes $6.5 million in ARPA funding available for this initiative.

     

    Continue Reading

  • Fourth Quarter 2025 Price and Inflation Expectations Survey

    Fourth Quarter 2025 Price and Inflation Expectations Survey

    Note: Survey responses were collected from November 10 to November 20.

    Firms’ Expectations of Price Growth Fell Relative to Last Quarter

    Third District firms reported that expected increases both for prices they will receive for their own goods and services and for U.S. inflation over the next four quarters moved down in the fourth quarter of 2025 compared with the third quarter. Their expectations for compensation held steady. Firms reported a similar increase in their own prices over the past year compared with last quarter.

    Firms Expect Smaller Rise in Own Prices and Steady Growth in Compensation Costs Relative to Last Quarter

    For the fourth quarter of 2025 through the fourth quarter of 2026, the firms’ mean forecast for their own prices was for an increase of 2.6 percent, down from 3.3 percent last quarter. Firms expected compensation costs per employee to rise 3.3 percent over the same time period, unchanged from last quarter. The mean forecast for U.S. inflation was 3.6 percent, down from 4.7 percent last quarter.

     

    Firms Expect Smaller Price Increases Compared with Their Current Price Growth

    Looking back over the past year (the fourth quarter of 2024 to the fourth quarter of 2025), firms reported that the prices they received for their own goods and services rose 3.0 percent, little changed from the 2.9 percent they reported last quarter and higher than the 2.6 percent growth they expect over the next four quarters.

    Reported Changes in Own Prices vs. Expectations

     

    Firms Expect Lower U.S. Inflation Relative to Last Quarter’s Expectation

    Firms’ median expectation for U.S. inflation declined to 3.0 percent from 3.3 percent, its second consecutive decrease and lowest reading in a year. The mean expectation also moved down, to 3.6 percent from 4.7 percent last quarter.

    One-Year-Ahead U.S. Inflation Expectations

     

    Long-Term Median Inflation Expectations Tick Up

    For the longer run, firms’ median expectation of the average annual price increase that U.S. consumers will experience over the next 10 years moved up to 4.0 percent, following nine consecutive quarters at 3.0 percent. The mean expectation dropped to 6.1 percent from 9.3 percent, after rising in five consecutive quarters.

    Ten-Year-Ahead U.S. Inflation Expectations

    Price and Inflation Expectations Survey

    Firm Type Current
    2025 Q4
    (%)
    Previous
    2025 Q3
    (%)
    Reported Change in Own Firm Prices
    Prices the respondent’s firm received (for its own goods
    and services sold) over the past four quarters
    All 3.0 2.9
    Manufacturing 2.9 3.7
    Nonmanufacturing 3.0 2.3

    Expected Change in Own Firm Prices
    Prices the respondent’s firm will receive (for its own goods
    and services sold) over the next four quarters
    All 2.6 3.3
    Manufacturing 2.9 3.8
    Nonmanufacturing 2.4 3.0

    Expected Change in Own Compensation
    Compensation the respondent’s firm will pay per employee
    (for wages and benefits) over the next four quarters

    All 3.3 3.3
    Manufacturing 3.2 3.3
    Nonmanufacturing 3.3 3.2

    Expected U.S. Inflation
    Prices U.S. consumers will pay for goods and services
    over the next four quarters

    All (median) 3.0 3.3
    All 3.6 4.7
    Manufacturing 3.2 4.5
    Nonmanufacturing 4.1 4.8

    Expected Long-Run U.S. Inflation
    Prices U.S. consumers will pay for goods and services
    over the next four quarters
    All (median) 4.0 3.0
    All 6.0 9.3
    Manufacturing 5.4 7.8
    Nonmanufacturing 6.6 10.3
    Notes: Results reflect data received through November 20, 2025. The numbers in the table represent the trimmed means of individual firm forecasts (percent changes) unless noted otherwise. For Long-Run U.S. Inflation forecasts, firms provided a 10-year annual-average change. The previous quarter’s results reflect forecasts made in 2025 Q3 for 2026 Q3.

    To see how reported and expected firm prices compare with U.S. CPI over time, see the PIES data explorer.

    For more information on how PIES data compare with U.S. CPI as well as with other inflation forecasts, see
    Introducing PIES.

    Continue Reading

  • Hartford Hospital Named Top Teaching Hospital | Hartford HealthCare

    Hartford Hospital Named Top Teaching Hospital | Hartford HealthCare

    << Back

    December 15, 2025

    Highlighting its nationally recognized achievements in patient safety and quality, Hartford Hospital has been named a Top Teaching Hospital, now five years in a row, by The Leapfrog Group, a national watchdog organization for health care safety and quality. This award is widely acknowledged as one of the most competitive awards American hospitals can receive.

    “This recognition, five years in a row, is one way to underscore the value of putting the patient at the center of everything we do,” said Cheryl Ficara, RN, MSN, NEA-BC, President of Hartford Hospital and Senior Vice President of Hartford HealthCare. “As a high reliability organization, we take error prevention very seriously. I commend our colleagues for upholding rigorous standards in every interaction and am proud of the critical work our team members do every day. This award highlights Hartford Hospital’s national standing as a place to receive and provide care.”

    Only 73 hospitals in the country received the Top Teaching award this year.

    The Leapfrog Group rates hospitals on how well they protect patients from preventable harm, including accidents, injuries and infections. The Leapfrog Top Teaching Hospital award is given to hospitals that publicly report their performance through the Leapfrog Hospital Survey and meet the high standards defined in the Top Hospitals methodology. This includes infection rates, maternity care and a hospital’s ability to prevent medication errors, among other standards. The rigorous standards are defined in each year’s Top Hospital Methodology.

    To qualify for the distinction, hospitals must rank top among peers on the Leapfrog Hospital Survey, which assesses hospital performance on the highest standards for quality and patient safety, and achieve top performance in their category.

    Continue Reading

  • County Seeking Nonprofit Tenant for Lasalle Building

    Mecklenburg County is requesting quotes from nonprofit organizations interested in serving as a tenant and service-provider at 2324 Lasalle St., Charlotte.

    The County is seeking a nonprofit organization dedicated to providing services towards academic success and upwards economic mobility for youth and families. The facility is in a high-need area, with several schools nearby.

    The ideal nonprofit will utilize the County-owned facility to provide long-term economic mobility focused programming, including academic and workforce services. They will also work with partners to develop additional service offerings.

    Applicants must have a vendor profile with the County to submit a response. For more information on vendor registration and how to submit a response, please visit the MeckProcure page.

    Responses must be emailed to [email protected] by Jan. 30, 2026, at 2 p.m. 

    See the full Request for Quotes (RFQ) document under the “View Published Solicitations” tab.  

    Continue Reading